Rocbrutinib

洛布替尼

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameRocbrutinib
Drug Alias NameLP-168NWP-775HS-10561HS10561
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsChronic UrticariaNeuromyelitis OpticaMultiple Sclerosis +[14
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesNewave Pharmaceutical Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Inactive CompaniesN/A
Active IndicationsChronic UrticariaNeuromyelitis OpticaMultiple Sclerosis +[13
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A